Cormedix Inc (CRMD)
5.165
-0.24
(-4.53%)
USD |
NASDAQ |
May 10, 16:00
5.165
0.00 (0.00%)
After-Hours: 20:00
Cormedix SG&A Expense (Quarterly): 13.38M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 13.38M |
September 30, 2023 | 7.803M |
June 30, 2023 | 7.010M |
March 31, 2023 | 7.610M |
December 31, 2022 | 5.575M |
September 30, 2022 | 4.628M |
June 30, 2022 | 5.052M |
March 31, 2022 | 4.751M |
December 31, 2021 | 4.553M |
September 30, 2021 | 3.837M |
June 30, 2021 | 3.356M |
March 31, 2021 | 4.601M |
December 31, 2020 | 3.789M |
September 30, 2020 | 3.692M |
June 30, 2020 | 3.233M |
March 31, 2020 | 3.165M |
December 31, 2019 | 2.678M |
September 30, 2019 | 2.631M |
June 30, 2019 | 2.572M |
March 31, 2019 | 1.985M |
December 31, 2018 | 2.213M |
September 30, 2018 | 2.012M |
June 30, 2018 | 1.946M |
March 31, 2018 | 1.903M |
December 31, 2017 | 1.968M |
Date | Value |
---|---|
September 30, 2017 | 1.992M |
June 30, 2017 | 2.051M |
March 31, 2017 | 2.641M |
December 31, 2016 | 2.433M |
September 30, 2016 | 2.318M |
June 30, 2016 | 1.969M |
March 31, 2016 | 2.050M |
December 31, 2015 | 2.267M |
September 30, 2015 | 2.949M |
June 30, 2015 | 2.355M |
March 31, 2015 | 2.693M |
December 31, 2014 | 1.524M |
September 30, 2014 | 1.587M |
June 30, 2014 | 1.703M |
March 31, 2014 | 2.513M |
December 31, 2013 | 1.524M |
September 30, 2013 | 0.5045M |
June 30, 2013 | 0.9087M |
March 31, 2013 | 0.5517M |
December 31, 2012 | 0.1976M |
September 30, 2012 | 0.7467M |
June 30, 2012 | 0.3766M |
March 31, 2012 | 0.5363M |
December 31, 2011 | 0.5392M |
September 30, 2011 | 0.877M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.572M
Minimum
Jun 2019
13.38M
Maximum
Dec 2023
4.943M
Average
4.553M
Median
Dec 2021
SG&A Expense (Quarterly) Benchmarks
BioXcel Therapeutics Inc | 9.603M |
ACADIA Pharmaceuticals Inc | 107.99M |
Cassava Sciences Inc | 4.058M |
Vertex Pharmaceuticals Inc | 342.70M |
Oragenics Inc | 1.754M |